My WebLink
|
Help
|
About
|
Sign Out
PC-2021-08
City of Pleasanton
>
BOARDS AND COMMISSIONS
>
PLANNING
>
RESOLUTIONS
>
2020 - PRESENT
>
2021
>
PC-2021-08
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
4/25/2022 10:50:33 AM
Creation date
4/25/2022 10:50:30 AM
Metadata
Fields
Template:
CITY CLERK
CITY CLERK - TYPE
RESOLUTIONS
DOCUMENT DATE
7/14/2021
DESTRUCT DATE
PERMANENT
DOCUMENT NO
PC-2021-08
NOTES
PUD-139, P20-0973, 10X GENOMICS, FINDING OF CONSISTENCY WITH GENERAL PLAN, 1701 SPRINGDALE AVE
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
3
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
Show annotations
View images
View plain text
RESOLUTION NO. PC-2021-08 <br /> A RESOLUTION OF THE PLANNING COMMISSION OF THE CITY OF PLEASANTON <br /> RECOMMENDING A FINDING OF CONSISTENCY WITH THE GENERAL PLAN <br /> FOR A DEVELOPMENT AGREEMENT FOR A PLANNED UNIT DEVELOPMENT (PUD) <br /> REZONING AND DEVELOPMENT PLAN FOR THE APPLICATION OF 10X GENOMICS <br /> AS FILED UNDER CASE NOS. PUD-139 and P20-0973 <br /> WHEREAS, on November 6, 2020, 10x Genomics ("Applicant") submitted applications for: <br /> (1) a Planned Unit Development (PUD) Rezoning to rezone the property at 1701 Springdale <br /> Avenue, Pleasanton from C-R (p) (Regional Commercial - peripheral sites) District to PUD-C-O <br /> (Planned Unit Development — Commercial-Office) District; (2) a PUD Development Plan to <br /> construct up to three new multi-story research and development, office and laboratory buildings <br /> totaling approximately 381,000 square feet, a parking structure, and related site improvements <br /> over multiple phases; as well as (3) make a finding of General Plan conformity for a related <br /> Development Agreement to vest the entitlements for the PUD Rezoning and Development Plan <br /> (collectively the "Project"); and <br /> WHEREAS, Government Code §§ 65865 through 65869.5, authorize a city to enter into <br /> binding development agreements with persons having legal interests in real property for the <br /> development of such property; and <br /> WHEREAS, 10x Genomics has applied to the City for a development agreement <br /> concerning the Project; and <br /> WHEREAS, at its duly noticed public meeting of May 26, 2021, the Planning Commission <br /> considered the written agenda report, all public testimony, relevant exhibits, and staff <br /> recommendations; and <br /> WHEREAS, at its duly noticed public meeting of May 26, 2021, the Planning Commission <br /> determined the Development Agreement is consistent with the City's General Plan. <br /> NOW, THEREFORE BE IT RESOLVED by the Planning Commission of the City of <br /> Pleasanton, based on the entire record of proceedings, including the oral and written agenda <br /> reports and all public comment and testimony: <br /> Section 1: Recommends the City Council find the proposed Project's Development Agreement <br /> is consistent with the City's General Plan based on the following: <br /> The Land Use Designation at 1701 Springdale Avenue, Pleasanton is "Retail/Highway/Service <br /> Commercial; Business and Professional Offices", which permits office uses. R&D and laboratory <br /> uses are not separately defined or identified as a land use category in the PMC; however, both <br /> are listed among a broad range of potential uses in the PMC's definition of"Light Industrial." R&D <br /> and laboratory uses are not expressly permitted in the C-R (p) District; thus, the Project would be <br /> consistent with the General Plan Land Use Designation if the subject site is rezoned to PUD. The <br /> proposed 381,000 sq. ft. of building area would result in a floor area ratio (FAR) of 60% for the <br /> subject site. This complies with the 60% maximum FAR permitted for the designated land use. <br /> The proposed Project would further several General Plan Goals, Programs, and Policies, <br />